Noom recently launched a microdosing program for GLP-1s. However, some are concerned about the use of compounded GLP-1s in this program, as they are not FDA-approved.
The post GLP-1s Come With High Price Tags and Major Side Effects. Could Microdosing Be the Answer? appeared first on MedCity News.
Driving value and efficiencies with intelligent automation for claims audit processes
Despite revenue growth, healthcare payers have faced increasing margin pressures over the past year as healthcare costs continue to climb. Introducing new efficiencies into key
